The market for biodefense is expected to grow at a CAGR of around 5.8% from 2020 to 2027 and expected to reach the market value of around US$ 19.1 Bn by 2027.
Biodefense is a method of detecting, preventing, or managing an attack involving biological weapons. It uses medical measures to protect people against bioterrorism. It includes medical research and preparations to defend against bioterrorist attacks as a result it include medicines and vaccinations. Moreover, bioterrorism or biological attack is the deliberate release of bacteria, viruses, or other germs to cause illness or death to the target population. These death or illness-causing organisms found in nature, but are made more harmful by increasing their ability to cause disease, spread, or resist medical treatment. This intentional release of deadly organisms adversely impacts the economy and human health and leads to the depletion of human resources..
The growing awareness regarding bioterrorism attacks in developed countries is driving the growth. The presence of favorable government initiatives in the U.S., as well as governments across major economies is also spending heavily on the R&D of vaccines, in order to stay prepared for any bioterrorism attacks. The growing investment from government in order to protect their population from any deadly virus, bacteria, or germs is additionally propelling the market growth. Furthermore, the rising risk of prevalence of the infectious disease with the ongoing COVID-19 pandemic is further expected to create potential growth over the forecast period.
On the other hand, low market penetration in underdeveloped economies is likely to hinder growth over the forecast period.
Segment Instance of Global Biodefense Market
Anthrax accounted for the maximum revenue share in the global market
In 2019, Anthrax is an infection caused by the bacterium Bacillus anthracis. It occurs mainly in four forms including skin, lungs, intestinal, and injection. It’s a serious illness caused by a spore-forming bacterium (Bacillus anthracis). The disease is mainly affected by direct or indirect contact with livestock and wild game. According to the World Health Organization (WHO), anthrax expert committee estimates of 1970, an aircraft release of 50 kg of anthrax over an urban, developed a population of 5 million would result in 250,000 casualties, of whom 95,000 would be expected to die without treatment and an additional 125,000 would be severely incapacitated. According to National Center for Biotechnology Information (NCBI), Anthrax bacteria are categorized as a tier 1 biological agent, because it can easily be transmitted from one person to another and have the potential of major impact on public health. In addition, the most common form of anthrax is a cutaneous disease, accounting for 90% or more of all cases worldwide.
North America accounted for the maximum revenue share in the global market
In 2019, North America had a potential share in the biodefense market, majorly the US contributed to the maximum revenue share in the regional market. National Institutes of Health supports and conducts a wide range of basic and clinical research, research training, and health information dissemination across all fields of biomedical and behavioral sciences. About 10 percent of the NIH budget supports intramural research projects conducted by nearly 6,000 NIH federal scientists located at NIH campus Bethesda, MD. Moreover, more than 80% of NIH’s budget goes to the extramural research community in the form of grants, contracts, and other awards.
Asia Pacific is anticipated to exhibit fastest growth over the forecast period from 2020 to 2027
Asia Pacific is anticipated to exhibit the fastest growth over the forecast period from 2020 to 2027. The major economies of the region are exhibiting advancements in technology in order to check both pathogens and benign microorganisms. The development and manufacturing of vaccines is another factor supporting the regional market growth. The increasing government investment in current and future policy initiatives, as a result, companies operating in the market, will witness significant growth in their revenues, by understanding the existing biosecurity and biodefense policies.
Key Market Players
The players profiled in the report include Altimmune Inc., Bavarian Nordic, Cleveland BioLabs, Elusys Therapeutics, Emergent BioSolutions Inc., Ichor Medical Systems, Ology Bioservices, PathSensors Inc., and Siga Technologies Inc.
Market By Product
Market By Geography
• Rest of Europe
• South Korea
• Rest of Asia-Pacific
• Rest of Latin America
Middle East & Africa
• South Africa
• Rest of Middle East & Africa
The market for biodefense is expected to reach a market value of around US$ 19.1 Bn by 2027.
The biodefense market is expected to grow at a CAGR of around 5.8% from 2020 to 2027.
Anthrax is the leading segment by application in the biodefense market
The growing awareness regarding bioterrorism attacks, presence of favorable government initiatives, growing investment from private players, and rising risk of prevalence of the infectious disease are some of the factors driving the market growth.
Altimmune Inc., Bavarian Nordic, Cleveland BioLabs, Elusys Therapeutics, Emergent BioSolutions Inc., Ichor Medical Systems, Ology Bioservices, PathSensors Inc., and Siga Technologies Inc. among others are some of the prominent players in the biodefense market.
North America held the maximum market share in the biodefense market
Asia Pacific is expected to be the fastest growing market over the forecast period